Bronchiectasis
Insmed Secures FDA Approval for First DPP1 Inhibitor in Lung Disease
Insmed; FDA approval; DPP1 inhibitor; Brensocatib; Brinsupri; bronchiectasis; lung disease
Insmed’s Brinsupri Receives First-Ever FDA Approval for Progressive Lung Disease
Brinsupri; Insmed; FDA approval; non-cystic fibrosis bronchiectasis; bronchiectasis; DPP1 inhibitor; brensocatib; progressive lung disease; neutrophil-mediated disease; first-in-class
Insmed’s Stocks Skyrocket Following Triumphant Phase III Results for Brensocatib in Bronchiectasis Treatment
Insmed, brensocatib, bronchiectasis, Phase III trial, lung disease, stock surge, New Drug Application, FDA approval, market value